Log in

Relevant bibliographies by topics / Oral delivery systems / Journal articles

To see the other types of publications on this topic, follow the link: Oral delivery systems.

Journal articles on the topic 'Oral delivery systems'

Author: Grafiati

Published: 4 June 2021

Last updated: 16 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Oral delivery systems.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Zaman, Muhammad, Junaid Qureshi, Hira Ejaz, Rai Muhammad Sarfraz, Hafeez Ullah Khan, Fazal Rehman Sajid, and Muhammad Shafiq ur Rehman. "Oral controlled release drug delivery system and Characterization of oral tablets; A review." Pakistan Journal of Pharmaceutical Research 2, no. 1 (January 27, 2016): 67. http://dx.doi.org/10.22200/pjpr.2016167-76.

Full text

Abstract:

Oral route of drug administration is considered as the safest and easiest route of drug administration. Control release drug delivery system is the emerging trend in the pharmaceuticals and the oral route is most suitable for such kind of drug delivery system. Oral route is more convenient for It all age group including both pediatric and geriatrics. There are various systems which are adopted to deliver drug in a controlled manner to different target sites through oral route. It includes diffusion controlled drug delivery systems; dissolution controlled drug delivery systems, osmotically controlled drug delivery systems, ion-exchange controlled drug delivery systems, hydrodynamically balanced systems, multi-Particulate drug delivery systems and microencapsulated drug delivery system. The systems are formulated using different natural, semi-synthetic and synthetic polymers. The purpose of the review is to provide information about the orally controlled drug delivery system, polymers which are used to formulate these systems and characterizations of one of the most convenient dosage form which is the tablets.

APA, Harvard, Vancouver, ISO, and other styles

2

Ranade, Vasant V. "Drug Delivery Systems 5A. Oral Drug Delivery." Journal of Clinical Pharmacology 31, no. 1 (January 1991): 2–16. http://dx.doi.org/10.1002/j.1552-4604.1991.tb01881.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Ranade, Vasant V. "Drug Delivery Systems 5B. Oral Drug Delivery." Journal of Clinical Pharmacology 31, no. 2 (February 1991): 98–115. http://dx.doi.org/10.1002/j.1552-4604.1991.tb03693.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Maroni, Alessandra, Lucia Zema, Matteo Cerea, and Maria Edvige Sangalli. "Oral pulsatile drug delivery systems." Expert Opinion on Drug Delivery 2, no. 5 (September 2005): 855–71. http://dx.doi.org/10.1517/17425247.2.5.855.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Bruschi, Marcos Luciano, and Osvaldo de Freitas. "Oral Bioadhesive Drug Delivery Systems." Drug Development and Industrial Pharmacy 31, no. 3 (March 1, 2005): 293–310. http://dx.doi.org/10.1081/ddc-200052073.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Bruschi, Marcos Luciano, and Osvaldo de Freitas. "Oral Bioadhesive Drug Delivery Systems." Drug Development and Industrial Pharmacy 31, no. 3 (January 2005): 293–310. http://dx.doi.org/10.1081/ddc-52073.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Kumar, P. S., P. Clark, M. C. Brinkman, and D. Saxena. "Novel Nicotine Delivery Systems." Advances in Dental Research 30, no. 1 (September 20, 2019): 11–15. http://dx.doi.org/10.1177/0022034519872475.

Full text

Abstract:

Electronic nicotine delivery systems (ENDS) are devices that contain a power source, a heating element, and a tank or cartridge containing an “e-liquid,” which is a mixture of nicotine and flavoring in a glycerol–propylene glycol vehicle. Their increasing popularity among adolescents might be attributed to aggressive marketing in physical venues, social media outlets, as well as irreversible changes caused by nicotine in the developing brains of youth and young adults, predisposing them to addictive behaviors. Adolescent ENDS users were 4 times more likely to initiate cigarette smoking, and the odds of quitting smoking were lower and, in many instances, delayed for those using ENDS. ENDS also renormalize cigarette-like behaviors, such as inhaling/exhaling smoke. The oral cavity is the initial point of contact of ENDS and the first affected system in humans. Oral health depends on an intricate balance in the interactions between oral bacteria and the human immune system, and dysbiosis of oral microbial communities underlies the etiology of periodontitis, caries, and oral cancer. Emerging evidence from subjects with periodontitis as well as periodontally healthy subjects demonstrates that e-cigarette use is associated with a compositional and functional shift in the oral microbiome, with an increase in opportunistic pathogens and virulence traits.

APA, Harvard, Vancouver, ISO, and other styles

8

Wong, Tin Wui. "Design of oral insulin delivery systems." Journal of Drug Targeting 18, no. 2 (October 5, 2009): 79–92. http://dx.doi.org/10.3109/10611860903302815.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

O'driscoll, Caitriona. "Micellar systems for oral drug delivery." Journal of Pharmacy and Pharmacology 50, S9 (September 1998): 13. http://dx.doi.org/10.1111/j.2042-7158.1998.tb02213.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Bernkop-Schnürch, Andreas. "Mucoadhesive systems in oral drug delivery." Drug Discovery Today: Technologies 2, no. 1 (March 2005): 83–87. http://dx.doi.org/10.1016/j.ddtec.2005.05.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Javanbakht, Siamak, and Ahmad Shaabani. "Carboxymethyl cellulose-based oral delivery systems." International Journal of Biological Macromolecules 133 (July 2019): 21–29. http://dx.doi.org/10.1016/j.ijbiomac.2019.04.079.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Sudhakar, Dr Uma, K. Ruth Gethsie, H. Priyanka, and SS Fathima Zinneerah. "Local drug delivery drugs and systems." International Journal of Applied Dental Sciences 6, no. 4 (October 1, 2020): 70–73. http://dx.doi.org/10.22271/oral.2020.v6.i4b.1047.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Thirupathi, Gorre, Samanthula Kumara Swamy, and Alli Ramesh. "Solid lipid nanocarriers as alternative drug delivery system for improved oral delivery of drugs." Journal of Drug Delivery and Therapeutics 10, no. 6-s (December 15, 2020): 168–72. http://dx.doi.org/10.22270/jddt.v10i6-s.4410.

Full text

Abstract:

Oral bioavailability of drugs is mainly limited due to the poor aqueous solubility, enhanced chemical degradation, reduced permeation and/or first pass metabolism. Various novel delivery systems are developed for improved oral bioavailability of these drugs such as modified orals, buccal, transdermal and osmotic delivery systems. Colloidal carrier systems such as nanoparticles, lipid nanoparticles, nanoemulsions, microspheres, liposomes, resealed erythrocytes and transfersomes were also developed to enhance the oral delivery. Among these, solid lipid nanocarriers (SLNs) also gain much attention on the enhancement of oral bioavailability. SLNs are submicron sized nanoparticles and composed of solid lipid, surfactants and cosurfactants. The enhanced oral bioavailability of poorly soluble drugs from SLNs might be due to the reduced particle size, bypassed presystemic metabolism, and enhanced gastric mucosa permeability. Vast literature is available for the advantages, limitations, preparation methods, evaluation parameters and application of SLNs in different routes. This review mainly focused on list of drugs developed as SLNs and considered as an alternative approach to enhance the oral bioavailability based on pharmacokinetic as well as pharmacodyanmic parameters was discussed. Keywords: Oral bioavailability, solubility, first-pass metabolism, solid lipid nanoparticles, pharmacokinetics, pharmacodynamics.

APA, Harvard, Vancouver, ISO, and other styles

14

Ellis, A. E. "Recent Development in Oral Vaccine Delivery Systems." Fish Pathology 30, no. 4 (1995): 293–300. http://dx.doi.org/10.3147/jsfp.30.293.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Tao, Sarah L., and Tejal A. Desai. "Gastrointestinal patch systems for oral drug delivery." Drug Discovery Today 10, no. 13 (July 2005): 909–15. http://dx.doi.org/10.1016/s1359-6446(05)03489-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Saigal, Nitin, Sanjula Baboota, Alka Ahuja, and Javed Ali. "Fast-dissolving intra-oral drug delivery systems." Expert Opinion on Therapeutic Patents 18, no. 7 (June 19, 2008): 769–81. http://dx.doi.org/10.1517/13543776.18.7.769.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Limmroth, Volker, Andrew J. Dowson, Hans-Christoph Diener, and Carl Dahl??f??? "Non-Oral Delivery Systems in Headache Therapy." American Journal of Drug Delivery 2, no. 1 (2004): 59–68. http://dx.doi.org/10.2165/00137696-200402010-00004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Lavelle, Ed C., and D. T. O’Hagan. "Delivery systems and adjuvants for oral vaccines." Expert Opinion on Drug Delivery 3, no. 6 (October 31, 2006): 747–62. http://dx.doi.org/10.1517/17425247.3.6.747.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Banerjee, Amrita, and Samir Mitragotri. "Intestinal patch systems for oral drug delivery." Current Opinion in Pharmacology 36 (October 2017): 58–65. http://dx.doi.org/10.1016/j.coph.2017.08.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Pandey, Parijat, Manisha Saini, and Neeta . "Mucoadhesive drug delivery system: an overview." Pharmaceutical and Biological Evaluations 4, no. 4 (August 1, 2017): 183. http://dx.doi.org/10.26510/2394-0859.pbe.2017.29.

Full text

Abstract:

The major objective of any dosage form is to deliver an optimum therapeutic amount of active agent to the proper site in the body to attain constant & maintenance of the desired drug concentration. Mucoadhesive drug delivery systems are effective delivery systems with various advantages as compared to other oral controlled release dosage forms in terms of drug delivery at specific sites with prolonged retention time of drugs at target sites. The main advantage of these systems includes avoiding first pass metabolism of the drugs and hence availability of high drug concentration at target site. Oral mucoadhesive systems have potential ability for controlled and extended release profile so as to get better performance and patient compliance. The present manuscript briefly reviews the benefits of mucoadhesive drug delivery systems, mechanisms involved in mucoadhesion, different factors affecting mucoadhesive drug delivery systems.

APA, Harvard, Vancouver, ISO, and other styles

21

Kang, Sung, Seok Hong, Yong-Kyu Lee, and Sungpil Cho. "Oral Vaccine Delivery for Intestinal Immunity—Biological Basis, Barriers, Delivery System, and M Cell Targeting." Polymers 10, no. 9 (August 27, 2018): 948. http://dx.doi.org/10.3390/polym10090948.

Full text

Abstract:

Most currently available commercial vaccines are delivered by systemic injection. However, needle-free oral vaccine delivery is currently of great interest for several reasons, including the ability to elicit mucosal immune responses, ease of administration, and the relatively improved safety. This review summarizes the biological basis, various physiological and immunological barriers, current delivery systems with delivery criteria, and suggestions for strategies to enhance the delivery of oral vaccines. In oral vaccine delivery, basic requirements are the protection of antigens from the GI environment, targeting of M cells and activation of the innate immune response. Approaches to address these requirements aim to provide new vaccines and delivery systems that mimic the pathogen’s properties, which are capable of eliciting a protective mucosal immune response and a systemic immune response and that make an impact on current oral vaccine development.

APA, Harvard, Vancouver, ISO, and other styles

22

Mathur, Prateek, Shruti Rawal, Bhoomika Patel, and Mayur M. Patel. "Oral Delivery of Anticancer Agents Using Nanoparticulate Drug Delivery System." Current Drug Metabolism 20, no. 14 (February 25, 2020): 1132–40. http://dx.doi.org/10.2174/1389200220666191007154017.

Full text

Abstract:

Background: Conventionally, anti-cancer agents were administered through the intravenous route. The major drawbacks associated with the intravenous route of administration are: severe side effects, need of hospitalization, nursing care, and palliative treatment. In order to overcome the drawbacks associated with the intravenous route of administration, oral delivery of anti-cancer agents has gained tremendous interest among the scientific fraternity. Oral delivery of anti-cancer agents principally leads to a reduction in the overall cost of treatment, and aids in improving the quality of life of patients. Bioavailability of drugs and inter-subject variability are the major concerns with oral administration of anti-cancer agents. Factors viz. physicochemical and biological barriers (pre-systemic metabolism and transmembrane efflux of the drug) are accountable for hampering oral bioavailability of anti-cancer agents can be efficiently overcome by employing nanocarrier based drug delivery systems. Oral delivery of anticancer agents by employing these drug delivery systems will not only improve the quality of life of patients but will also provide pharmacoeconomic advantage and lead to a reduction in the overall cost of treatment of life-threatening disease like cancer. Objective: This article aims to familiarize the readers with some of the recent advancements in the field of nanobased drug delivery systems for oral delivery of anticancer agents. Conclusion: Advancement in the field of nanotechnology-based drug delivery systems has opened up gateways for the delivery of drugs that are difficult to administer orally. Oral delivery of anti-cancer agents by these drug delivery systems will not only improve the quality of life of patients but will also provide pharmacoeconomic advantage and lead to a reduction in the overall cost of treatment of life-threatening disease like cancer.

APA, Harvard, Vancouver, ISO, and other styles

23

Leonaviciute, Gintare, and Andreas Bernkop-Schnürch. "Self-emulsifying drug delivery systems in oral (poly)peptide drug delivery." Expert Opinion on Drug Delivery 12, no. 11 (August 24, 2015): 1703–16. http://dx.doi.org/10.1517/17425247.2015.1068287.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Mazzaferro, Silvia, Kawthar Bouchemal, and Gilles Ponchel. "Oral delivery of anticancer drugs III: formulation using drug delivery systems." Drug Discovery Today 18, no. 1-2 (January 2013): 99–104. http://dx.doi.org/10.1016/j.drudis.2012.08.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Nadigoti, Jagadeesh, and Shayeda. "Floating Drug Delivery Systems." International Journal of Pharmaceutical Sciences and Nanotechnology 2, no. 3 (November 30, 2009): 595–604. http://dx.doi.org/10.37285/ijpsn.2009.2.3.2.

Full text

Abstract:

Management of illness through medication is entering a new era in which growing number of novel drug delivery systems are being employed and are available for therapeutic use. Oral sustained release gastro-retentive dosage forms (GRDFs) offer many advantages for drugs with absorption from upper parts of gastrointestinal tract and for those acting locally in the stomach, improving the bioavailability of the medication. Floating Drug Delivery Systems (FDDS) is one amongst the GRDFs used to achieve prolonged gastric residence time. Multiple unit FDDS avoid “all-or-nothing” gastric emptying nature of single unit systems. Apart from the background, formulation aspects and evaluation of FDDS, recent developments are also covered in this review.

APA, Harvard, Vancouver, ISO, and other styles

26

Lakavath, Sunil Kumar. "Novel Delivery System Used for Oral Bioavailability Enhancement of Poorly Water Soluble Drugs." Journal of Drug Delivery and Therapeutics 10, no. 6-s (December 15, 2020): 139–44. http://dx.doi.org/10.22270/jddt.v10i6-s.4613.

Full text

Abstract:

Majority of the drugs used for the treatment of various diseases are administered by oral route using conventional delivery. The major drawback of the oral administration is the poor bioavailability due to the poor water solubility, chemical stability and pre-systemic metabolism. Numerous researches are going on for the improvement of oral bioavailability of drugs using novel drug delivery systems as an alternative to conventional delivery systems. Majority of the novel delivery system includes; solid dispersion, sustained, controlled buccal, gastro retentive, nano carrier delivery systems such as lipid nanoparticles, and self-emulsifying systems. The oral bioavailability improvement by these delivery systems might be due to the increased particle size, improved dissolution and/or permeation and subsequently bioavailability of the drugs. In this review, we attempt to discuss the various novel delivery systems developed for the enhancement of oral bioavailability of poorly water soluble therapeutics. Keywords: Oral bioavailability, poor solubility, stability, metabolism, novel delivery systems, nano carriers.

APA, Harvard, Vancouver, ISO, and other styles

27

Politis, Stavros N., and Dimitrios M. Rekkas. "Recent Advances in Pulsatile Oral Drug Delivery Systems." Recent Patents on Drug Delivery & Formulation 7, no. 2 (May 1, 2013): 87–98. http://dx.doi.org/10.2174/1872211311307020001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Al-Achi, A., and R. Greenwood. "Erythrocytes as Oral Delivery Systems for Human Insulin." Drug Development and Industrial Pharmacy 24, no. 1 (January 1998): 67–72. http://dx.doi.org/10.3109/03639049809082354.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Fukumori, Shiro, and Yasuhiro Tsuji. "Drug delivery systems (DDS) for oral antimicrobial therapy." Drug Delivery System 33, no. 1 (January 25, 2018): 18–25. http://dx.doi.org/10.2745/dds.33.18.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Stanley, Theodore H., and Michael A. Ashburn. "Novel delivery systems: Oral transmucosal and intranasal transmucosal." Journal of Pain and Symptom Management 7, no. 3 (April 1992): 163–71. http://dx.doi.org/10.1016/s0885-3924(06)80009-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Attarwala, Husain, Murui Han, Jonghan Kim, and Mansoor Amiji. "Oral nucleic acid therapy using multicompartmental delivery systems." Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 10, no. 2 (May 24, 2017): e1478. http://dx.doi.org/10.1002/wnan.1478.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Somavarapu, S., V. W. Bramwell, and H. O. Alpar. "Oral Plasmid DNA Delivery Systems for Genetic Immunisation." Journal of Drug Targeting 11, no. 8-10 (January 2003): 547–53. http://dx.doi.org/10.1080/10611860410001683022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

He, Shiming, Zhongcheng Liu, and Donggang Xu. "Advance in oral delivery systems for therapeutic protein." Journal of Drug Targeting 27, no. 3 (July 17, 2018): 283–91. http://dx.doi.org/10.1080/1061186x.2018.1486406.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Gazzaniga, Andrea, Alessandra Maroni, Maria Edvige Sangalli, and Lucia Zema. "Time-controlled oral delivery systems for colon targeting." Expert Opinion on Drug Delivery 3, no. 5 (September 2006): 583–97. http://dx.doi.org/10.1517/17425247.3.5.583.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Kalepu, Sandeep, Mohanvarma Manthina, and Veerabhadhraswamy Padavala. "Oral lipid-based drug delivery systems – an overview." Acta Pharmaceutica Sinica B 3, no. 6 (December 2013): 361–72. http://dx.doi.org/10.1016/j.apsb.2013.10.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Knuth, Kim, Mansoor Amiji, and Joseph R. Robinson. "Hydrogel delivery systems for vaginal and oral applications." Advanced Drug Delivery Reviews 11, no. 1-2 (July 1993): 137–67. http://dx.doi.org/10.1016/0169-409x(93)90030-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Savastano, Louis, Hans Leuenberger, and Hans Peter Merkle. "Membrane modulated dissolution of oral drug delivery systems." Pharmaceutica Acta Helvetiae 70, no. 2 (July 1995): 117–24. http://dx.doi.org/10.1016/0031-6865(94)00056-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Gupta, Brahma Prakash, Navneet Thakur, Nishi P. Jain, Jitendra Banweer, and Surendra Jain. "Osmotically Controlled Drug Delivery System with Associated Drugs." Journal of Pharmacy & Pharmaceutical Sciences 13, no. 4 (November 20, 2010): 571. http://dx.doi.org/10.18433/j38w25.

Full text

Abstract:

Conventional drug delivery systems have slight control over their drug release and almost no control over the effective concentration at the target site. This kind of dosing pattern may result in constantly changing, unpredictable plasma concentrations. Drugs can be delivered in a controlled pattern over a long period of time by the controlled or modified release drug delivery systems. They include dosage forms for oral and transdermal administration as well as injectable and implantable systems. For most of drugs, oral route remains as the most acceptable route of administration. Certain molecules may have low oral bioavailability because of solubility or permeability limitations. Development of an extended release dosage form also requires reasonable absorption throughout the gastro-intestinal tract (GIT). Among the available techniques to improve the bioavailability of these drugs fabrication of osmotic drug delivery system is the most appropriate one. Osmotic drug delivery systems release the drug with the zero order kinetics which does not depend on the initial concentration and the physiological factors of GIT. This review brings out new technologies, fabrication and recent clinical research in osmotic drug delivery.

APA, Harvard, Vancouver, ISO, and other styles

39

Zaric, Bozidarka L., Milan Obradovic, Emina Sudar-Milovanovic, Jovan Nedeljkovic, Vesna Lazic, and Esma R. Isenovic. "Drug Delivery Systems for Diabetes Treatment." Current Pharmaceutical Design 25, no. 2 (May 28, 2019): 166–73. http://dx.doi.org/10.2174/1381612825666190306153838.

Full text

Abstract:

Background:Insulin is essential for the treatment of Type 1 diabetes mellitus (T1DM) and is necessary in numerous cases of Type 2 diabetes mellitus (T2DM). Prolonged administration of anti-diabetic therapy is necessary for the maintenance of the normal glucose levels and thereby preventing vascular complications. A better understanding of the disease per se and the technological progress contribute to the development of new approaches with the aim to achieve better glycemic control.Objective:Current therapies for DM are faced with some challenges. The purpose of this review is to analyze in detail the current trends for insulin delivery systems for diabetes treatment.Results:Contemporary ways have been proposed for the management of both types of diabetes by adequate application of drug via subcutaneous, buccal, oral, ocular, nasal, rectal and pulmonary ways. Development of improved oral administration of insulin is beneficial regarding mimicking physiological pathway of insulin and minimizing the discomfort of the patient. Various nanoparticle carriers for oral and other ways of insulin delivery are currently being developed. Engineered specific properties of nanoparticles (NP): controlling toxicity of NP, stability and drug release, can allow delivery of higher concentration of the drug to the desired location.Conclusions:The successful development of any drug delivery system relies on solving three important issues: toxicity of nanoparticles, stability of nanoparticles, and desired drug release rate at targeted sites. The main goals of future investigations are to improve the existing therapies by pharmacokinetic modifications, development of a fully automatized system to mimic insulin delivery by the pancreas and reduce invasiveness during admission.

APA, Harvard, Vancouver, ISO, and other styles

40

Moodley, Kovanya, Viness Pillay, Yahya E. Choonara, Lisa C. du Toit, Valence M. K. Ndesendo, Pradeep Kumar, Shivaan Cooppan, and Priya Bawa. "Oral Drug Delivery Systems Comprising Altered Geometric Configurations for Controlled Drug Delivery." International Journal of Molecular Sciences 13, no. 1 (December 22, 2011): 18–43. http://dx.doi.org/10.3390/ijms13010018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Patel, A. R., and K. P. Velikov. "Colloidal delivery systems in foods: A general comparison with oral drug delivery." LWT - Food Science and Technology 44, no. 9 (November 2011): 1958–64. http://dx.doi.org/10.1016/j.lwt.2011.04.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Mahmood, Arshad, Felix Prüfert, Nuri Ari Efiana, Muhammad Imtiaz Ashraf, Martin Hermann, Shah Hussain, and Andreas Bernkop-Schnürch. "Cell-penetrating self-nanoemulsifying drug delivery systems (SNEDDS) for oral gene delivery." Expert Opinion on Drug Delivery 13, no. 11 (August 4, 2016): 1503–12. http://dx.doi.org/10.1080/17425247.2016.1213236.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

M., Udaya Sakthi, Josephine Ritashinita Lobo F., and Kiran B. Uppuluri. "Self Nano Emulsifying Drug Delivery Systems for Oral Delivery of Hydrophobic Drugs." Biomedical & Pharmacology Journal 6, no. 2 (December 30, 2013): 355–62. http://dx.doi.org/10.13005/bpj/425.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Li, Ping, Hanne Mørck Nielsen, and Anette Müllertz. "Oral delivery of peptides and proteins using lipid-based drug delivery systems." Expert Opinion on Drug Delivery 9, no. 10 (August 17, 2012): 1289–304. http://dx.doi.org/10.1517/17425247.2012.717068.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Kanuganti, Swetha, Raju Jukanti, Prabhakar R. Veerareddy, and Suresh Bandari. "Paliperidone-Loaded Self-Emulsifying Drug Delivery Systems (SEDDS) for Improved Oral Delivery." Journal of Dispersion Science and Technology 33, no. 4 (April 2012): 506–15. http://dx.doi.org/10.1080/01932691.2011.574920.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Nachtigall, Lila E. "Emerging delivery systems for estrogen replacement: Aspects of transdermal and oral delivery." American Journal of Obstetrics and Gynecology 173, no. 3 (September 1995): 993–97. http://dx.doi.org/10.1016/0002-9378(95)90249-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Rao, Sripriya Venkata Ramana, Payal Agarwal, and Jun Shao. "Self-nanoemulsifying drug delivery systems (SNEDDS) for oral delivery of protein drugs." International Journal of Pharmaceutics 362, no. 1-2 (October 2008): 10–15. http://dx.doi.org/10.1016/j.ijpharm.2008.05.016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Venkata Ramana Rao, Sripriya, and Jun Shao. "Self-nanoemulsifying drug delivery systems (SNEDDS) for oral delivery of protein drugs." International Journal of Pharmaceutics 362, no. 1-2 (October 2008): 2–9. http://dx.doi.org/10.1016/j.ijpharm.2008.05.018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Mali, Audumbar Digambar, Ritesh Bathe, and Manojkumar Patil. "An updated review on transdermal drug delivery systems." International Journal of Advances in Scientific Research 1, no. 6 (July 30, 2015): 244. http://dx.doi.org/10.7439/ijasr.v1i6.2243.

Full text

Abstract:

Transdermal drug delivery systems (TDDS), also known as patches, are dosage forms designed to deliver a therapeutically effective amount of drug across a patients skin. In order to deliver therapeutic agents through the human skin for systemic effects, the comprehensive morphological, biophysical and physicochemical properties of the skin are to be considered. Transdermal delivery provides a leading edge over injectables and oral routes by increasing patient compliance and avoiding first pass metabolism respectively. Transdermal delivery not only provides controlled, constant administration of the drug, but also allows continuous input of drugs with short biological half-lives and eliminates pulsed entry into systemic circulation, which often causes undesirable side effects. The TDDS review articles provide valuable information regarding the transdermal drug delivery systems and its evaluation process details as a ready reference for the research scientist who is involved in TDDS. With the advancement in technology Pharma industries have trendified all its resources. Earlier we use convectional dosage form but now we use novel drug delivery system. One of greatest innovation of novel drug delivery is transdermal patch. The advantage of transdermal drug delivery system is that it is painless technique of administration of drugs.

APA, Harvard, Vancouver, ISO, and other styles

50

Schoener, C. A., and N. A. Peppas. "Oral delivery of chemotherapeutic agents: background and potential of drug delivery systems for colon delivery." Journal of Drug Delivery Science and Technology 22, no. 6 (2012): 459–68. http://dx.doi.org/10.1016/s1773-2247(12)50081-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!